Profiling protein post-translational modifications in plasma-derived extracellular vesicles across breast cancer subtypes.
Analyzing vesicles in blood reveals breast cancer subtype differences without tissue biopsy, potentially simplifying treatment selection decisions.
This Genome Biology study profiled protein post-translational modifications (PTMs) in plasma-derived extracellular vesicles to address breast cancer subtype discrimination, finding distinct PTM signatures across triple-negative, luminal A/B, and HER2-positive subtypes. The approach provides a novel EV-based liquid biopsy avenue for precision subtype characterization without tissue biopsy, with downstream implications for treatment selection.
What the study was
- Study design
- Exploratory omics/proteomic profiling study
- Population
- Breast cancer patients with distinct subtypes (triple-negative, luminal A/B, HER2-positive)
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- Genome Biol
Why it surfaced
Novel EV-PTM profiling approach for breast cancer subtype discrimination from plasma is highly novel and potentially impactful; Genome Biol venue reinforces scientific rigor; confidence medium as sample sizes not retrieved.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.